Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus Target Price from Analysts
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year […]
